Lenvatinib Viatris (Lenvatinib)

Lenvatinib blocks the activity of multiple receptor tyrosine kinases such as VEGFR, FGFR, PDGFRα, RET and KIT. By inhibiting these pathways, the drug reduces new blood‑vessel formation (angiogenesis) and directly suppresses cancer cell proliferation, leading to slowed tumour growth across a range of cancer types.

The specific dose of Lenvatinib Viatris is determined by the prescribing clinician based on the patient’s condition, body weight, renal and hepatic function, and other individual factors. Healthcare professionals follow the approved prescribing information and adjust the dose as needed for safety and efficacy.

Safety data for Lenvatinib in pregnancy and lactation are limited. The drug is generally not recommended for use during pregnancy or while breastfeeding because potential risks to the fetus or infant cannot be ruled out. Women of child‑bearing potential should use effective contraception during treatment.

To order Lenvatinib Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenvatinib distinguishes itself by targeting a broader spectrum of kinases, including VEGFR, FGFR, PDGFRα, RET and KIT, whereas some alternatives such as sorafenib focus mainly on VEGFR and RAF pathways. This broader inhibition may offer efficacy benefits in tumours that rely on multiple signalling routes, but safety profiles also differ and must be considered.

Lenvatinib should be stored at room temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight and excessive heat. Ensure the packaging remains sealed until use to maintain product stability.

Lenvatinib is taken orally, usually as a tablet, with or without food according to the prescriber’s instructions. Patients should swallow the tablet whole with water and follow any specific timing recommendations provided by their healthcare professional.

Serious adverse events linked to Lenvatinib include arterial thromboembolic events, severe hepatic impairment, gastrointestinal perforation or fistula formation, significant hemorrhage, and reversible posterior leukoencephalopathy syndrome. Patients should be monitored closely for these conditions, and treatment should be discontinued if they occur.

Lenvatinib is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. It should also be avoided in individuals with uncontrolled hypertension, recent major cardiovascular events, or active severe infections, unless the prescribing physician determines that the benefits outweigh the risks.